New Diarylamine KV10.1 Inhibitors and Their Anticancer Potential

Expression of the voltage-gated potassium channel K(V)10.1 (Eag1) has been detected in over 70% of human cancers, making the channel a promising new target for new anticancer drug discovery. A new structural class of K(V)10.1 inhibitors was prepared by structural optimisation and exploration of the structure-activity relationship of the previously published hit compound ZVS-08 (1) and its optimised analogue 2. The potency and selectivity of the new inhibitors between K(V)10.1 and hERG were investigated using whole-cell patch-clamp experiments. We obtained two new optimised K(V)10.1 inhibitors, 17a and 18b, with improved nanomolar IC50 values of 568 nM and 214 nM, respectively. Compound 17a exhibited better ratio between IC50 values for hEAG1 and hERG than previously published diarylamine inhibitors. Compounds 17a and 18b moderately inhibited the growth of the K(V)10.1-expressing cell line MCF-7 in two independent assays. In addition, 17a and 18b also inhibited the growth of hERG-expressing Panc-1 cells with higher potency compared with MCF-7 cells. The main obstacle for newly developed diarylamine K(V)10.1 inhibitors remains the selectivity toward the hERG channel, which needs to be addressed with targeted drug design strategies in the future.

Automated summary

Expression of K(V)10.1 has been detected in human cancers, making it a potential target for anticancer drugs. New inhibitors with improved potency and selectivity were developed through structural optimisation.